Exelixis logo
Exelixis EXEL
$ 51.24 1.24%
report update icon

Quarterly report 2026-Q2
added 08-05-2026

Exelixis Income Statement 2026-2008 | EXEL

Brief overview of profit and loss at Exelixis

The figures are compared over a five-year interval. Exelixis reported revenue of 1.4 billion dollars in 2021 and 2.3 billion dollars by 2026. The cumulative result was +61.7%, corresponding to roughly 10.1% per year. The company expanded its sales base at a healthy rate.

Gross profit changed from 1.4 billion dollars to 2.2 billion dollars (+61.8%). Direct costs broadly followed the top-line trend. Comparing the endpoints gives gross margins of 96.3% and 96.4%. There was no meaningful shift in gross profitability.

The operating result measured by EBITDA moved from $300 million to $901 million, or +200.1%. The operating result outpaced sales and points to improving efficiency. EBITDA margin moved from 20.9% to 38.8%. Higher profitability strengthens the quality of operating growth.

Net income changed from $231 million to $783 million (+238.7%). The latest figure was the best within the selected horizon.

The market value of the business moved from 5.8 billion dollars to 11.7 billion dollars, or +103.5%. Investors responded cautiously to the improvement in the business.

Overall conclusion

The results point to consistent and sustainable progress. The strongest signals are steady gross profitability, a larger revenue base and positive operating leverage. Further direction will depend on top-line growth, operating profitability, and net income.

Annual Income Statement Exelixis

2026 2025 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Market Cap

11.7 B 9.51 B 6.95 B 5.51 B 5.76 B 5.2 B 5.2 B 6.93 B 8.89 B 967 M 967 M 363 M 1.29 B 765 M 708 M 531 M 549 M -

Shares

272 M 290 M 318 M 322 M 315 M 303 M 303 M 298 M 294 M 209 M 209 M 194 M 184 M 160 M 126 M 109 M 107 M -

Historical Prices

43.1 32.8 21.8 17.1 18.3 20.1 17.6 19.7 30.4 14.9 5.64 1.44 6.13 4.57 4.74 4.89 5.13 6.11

Net Income

783 M 521 M 208 M 182 M 231 M 321 M 321 M 690 M 154 M -170 M -170 M -269 M -245 M -148 M 75.7 M -92.3 M -135 M -

Revenue

2.32 B 2.17 B 1.83 B 1.61 B 1.43 B 968 M 968 M 854 M 452 M 37.2 M 37.2 M 25.1 M 31.3 M 47.4 M 290 M 185 M 152 M -

Cost of Revenue

83.7 M 76.2 M 72.5 M 57.9 M 52.9 M 33.1 M - 26.3 M 15.1 M 6.55 M - - - - - - - -

Gross Profit

- - - - - 935 M 935 M 827 M 437 M 33.3 M 33.3 M 23.1 M 30.2 M 47.4 M 290 M - - -

Operating Income

872 M 605 M 171 M 201 M 287 M 369 M - 439 M 166 M -28.1 M -121 M -224 M -201 M -122 M 89.5 M -91.4 M -122 M -

Interest Expense

-198 K -133 K 93 K -197 K -184 K - - - 8.68 M 33.1 M 48.7 M 48.6 M 45.3 M 27.1 M 16.3 M 9.34 M 12.7 M -

EBITDA

901 M 633 M 197 M 222 M 300 M 378 M 378 M 447 M 167 M -95 M -119 M -214 M -196 M -102 M 88.4 M -80.9 M -109 M -

Operating Expenses

- - - - - 598 M 565 M 415 M 287 M 159 M 154 M 240 M 230 M 170 M 200 M 276 M 274 M -

General and Administrative Expenses

519 M 492 M 543 M 460 M 402 M 228 M 228 M 206 M 159 M 57.3 M 57.3 M 50.8 M 51 M 31.8 M 33.1 M 33 M 34.4 M -

All numbers in USD currency

Quarterly Income Statement Exelixis

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

251 M 258 M 262 M 268 M 273 M 279 M 282 M 286 M 289 M 301 M 303 M 315 M 324 M 324 M 324 M 322 M 321 M 320 M 319 M 315 M 314 M 312 M 305 M 309 M 308 M 305 M - 303 M 302 M 301 M 300 M 298 M 297 M 296 M 296 M 294 M 293 M 291 M 290 M 256 M 229 M 228 M 228 M 218 M 196 M 196 M 196 M 195 M 195 M 192 M 185 M 184 M 184 M 184 M 184 M 166 M 149 M 142 M 136 M 129 M 136 M 136 M

Net Income

212 M 210 M - 194 M 185 M 160 M - 118 M 226 M 37.3 M - 1.04 M 81.2 M 40 M - 73.2 M 70.7 M 68.6 M 28.4 M 38.2 M 96.1 M 1.6 M 68.7 M -32 M 66.8 M 48.6 M - 97.5 M 79 M 75.8 M 360 M 127 M 87.5 M 116 M 38.5 M 81.4 M 17.7 M 16.7 M 35.1 M -11.3 M -34.8 M -59.2 M -41.6 M -162 M -41.4 M -33.2 M -58 M -62.6 M -73.4 M -74.6 M -70.7 M -67.1 M -62.2 M -44.7 M -52.2 M -32.8 M -36.5 M -26.2 M 46.3 M 77.9 M -21 M -27.5 M

Revenue

629 M 611 M - 598 M 568 M 555 M - 540 M 637 M 425 M - 472 M 470 M 409 M - 412 M 419 M 356 M 270 M 328 M 385 M 270 M 240 M 231 M 259 M 227 M - 272 M 240 M 215 M 229 M 225 M 186 M 214 M 120 M 153 M 99 M 80.9 M 77.6 M 62.2 M 36.3 M 15.4 M 9.94 M 9.85 M 7.99 M 9.39 M 7.35 M 6.29 M 6.56 M 4.9 M 4.35 M 5.47 M 11.9 M 9.67 M 7.81 M 13.3 M 7.81 M 18.5 M 94.3 M 128 M 32.2 M 35.9 M

Cost of Revenue

20.7 M 20 M - 18.6 M 19.5 M 19.2 M - 17.3 M 17.7 M 21.3 M - 18.8 M 17.7 M 14.3 M - 15.3 M 13.5 M 13.2 M - 11.9 M 14.9 M 13.2 M - 8.72 M 9.22 M 9.29 M - 7.54 M 7.54 M 7.5 M - 7.36 M 6 M 5.64 M - 4.66 M - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - 191 M - - - 184 M 160 M 170 M 185 M - 184 M 186 M 172 M 169 M 156 M 140 M 129 M 91.5 M 91.8 M 85 M 65.7 M 50.1 M 40.3 M 30.1 M 8.41 M 8.92 M 8.43 M 7.31 M 8.62 M 6.67 M 5.72 M 6.08 M 4.6 M 4.08 M 5.18 M 11.6 M 9.39 M - - - - - - - -

Operating Income

248 M 251 M - 237 M 214 M 187 M - 136 M 276 M 29.5 M - -17.6 M 77.8 M 28.8 M - 82.6 M 83.7 M 83.2 M 24.3 M 51.6 M 123 M -4.61 M 77.3 M -42.6 M 75.5 M 52.8 M - 116 M 92 M 84.6 M 112 M 125 M 85.8 M 116 M 37.4 M 81.2 M 27.1 M 20.2 M 38.9 M 7.26 M -25.1 M -49.1 M -31.6 M -35.8 M -31.3 M -22.8 M -46.2 M -51.6 M -61.7 M -65 M - -55.9 M -51.3 M -34 M - -25.4 M -32.7 M -22.3 M - 79.7 M -18 M -23.7 M

Interest Expense

54 K 219 K - -49 K 50 K -245 K - -29 K -287 K -89 K - 289 K -5 K -54 K - -69 K 45 K 164 K - -19 K -11 K -90 K - 565 K - 6 K - -140 K 803 K 25 K - 1 K - - - - 4.26 M 4.42 M - 7.83 M 10.5 M 10.3 M - 40.7 M 12 M 12.4 M - 12.3 M 12.1 M 11.8 M - 11.4 M 11.2 M 11.1 M - 7.68 M 4.09 M 4 M - 4.14 M 4.16 M 3.94 M

EBITDA

262 M 258 M - - - 194 M - - - 35.8 M - - - 35.7 M - 97.5 M 93 M 87.7 M 24.3 M 63.3 M 130 M -1.38 M 77.3 M -35.8 M 79.9 M 55 M - 122 M 96 M 86.5 M 112 M 128 M 86.9 M 117 M 37.4 M 82 M 27.7 M 20.5 M 38.9 M 8.02 M -24.7 M -48.9 M -31.6 M -34.7 M -30.6 M -22.5 M -46.2 M -48.6 M -60.6 M -64.5 M - -53.5 M -49.7 M -33.2 M - -21.4 M -30.1 M -21.1 M - 84.7 M -14.1 M -21.8 M

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - - - 156 M 148 M 131 M - 100 M 100 M 97.4 M - 71.3 M 71.9 M 60.7 M - 54.9 M 61.4 M 64.6 M - 45.6 M 39.3 M 32.1 M - 57.9 M 68.2 M 69.9 M - 61.4 M 63.2 M 43.7 M - 38.8 M 40.5 M 40.8 M - 48.6 M 50.2 M 59.6 M

General and Administrative Expenses

148 M 140 M - 124 M 135 M 137 M - 112 M 132 M 114 M - 138 M 142 M 131 M - 115 M 123 M 103 M - 102 M 98.5 M 102 M - 88.2 M 59.8 M 62.9 M - 51.3 M 58.8 M 60.1 M - 48.1 M 51.9 M 54 M - 38.1 M 40.7 M 34.3 M - 32.5 M 35.8 M 34.9 M - 17.8 M 12.8 M 9.53 M - 9.91 M 16.5 M 14.7 M - 13.6 M 13.2 M 10.5 M - 7.34 M 6.76 M 7.9 M - 8.17 M 8.78 M 9.16 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Exelixis (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.19 5.31 % $ 14.5 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 4.37 0.23 % $ 958 M britainBritain
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
BeyondSpring BeyondSpring
BYSI
$ 0.84 34.27 % $ 34.5 M usaUSA
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Cerus Corporation Cerus Corporation
CERS
$ 2.98 4.93 % $ 568 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.41 4.17 % $ 225 M israelIsrael
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Champions Oncology Champions Oncology
CSBR
$ 5.1 2.63 % $ 70.5 M usaUSA
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 3.98 1.86 % $ 2.66 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 58.47 4.37 % $ 1.68 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 21.5 1.56 % $ 308 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 15.47 1.91 % $ 2.08 B canadaCanada
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 3.9 0.24 % $ 270 M britainBritain
Beam Therapeutics Beam Therapeutics
BEAM
$ 26.75 0.91 % $ 2.65 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 67.36 0.99 % $ 12.9 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada